NDAs: Impurities in Drug Substances

Administrative guidance, not enacted legislation. This captured publisher edition preserves the listed document and attachments; later developments are not independently consolidated.

Guidance for Industry
NDAs: Impurities in Drug Substances
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
February 2000
CMC

Guidance for Industry
NDAs: Impurities in Drug Substances
Additional copies are available from:
Drug Information Branch, HFD-210
Center for Drug Evaluation and Research
5600 Fishers Lane, Rockville, MD 20857 (Tel) 301-827-4573
Internet at http://www.fda.gov/cder/guidance/index.htm
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
February 2000
CMC

Guidance For Industry1
NDAs: Impurities in Drug Substances
This guidance recommends that applicants refer to Q3A Impurities in New Drug Substances (January 4, 1996,
61 FR 371) when seeking guidance on identification, qualification, and reporting of impurities in drug substances
that are not considered new drug substances. Although Q3A was developed by the International Conference on
Harmonisation (ICH) to provide guidance on the information that should be provided in a new drug application
(NDA) in support of impurities in new drug substances that are produced by chemical syntheses, the Agency
believes that the guidance provided there on identification, qualification, and reporting of impurities should also be
considered when evaluating impurities in drug substances produced by chemical syntheses that are not
considered new drug substances.2
This recommendation applies to applicants planning to submit NDAs and supplements for changes in drug
substance synthesis or process. It also applies to holders of Type II drug master files (DMFs) that support such
applications. Applicants should note that this recommendation would not apply to DMFs cited in an NDA or
supplement if the DMF information has been deemed acceptable for that dosage form, route of administration,
and daily intake prior to the publication of the final version of this guidance. Examples of NDAs affected by the
recommendation include those submitted for new dosage forms of already approved drug products, or drug
products containing two or more active moieties that are individually used in already approved drug products but
have not previously been approved or marketed together in a drug product.
This guidance does not apply to applications for biological, biotechnological, peptide, oligonucleotide,
radiopharmaceutical, fermentation and semisynthetic products derived therefrom, herbal products, or crude
products of animal or plant origin, nor does it apply to ANDAs. Guidance on drug substances used for ANDA
products is available in FDA's guidance on ANDAs: Impurities in Drug Substances (November 1999).
1 This guidance has been prepared by the Drug Substance Technical Committee of the Chemistry, Manufacturing, and Controls
Coordinating Committee in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration. This guidance
represents the Agency's current thinking on reporting impurities in drug substances for certain NDAs and DMFs. It does not create or confer
any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach
satisfies the requirements of the applicable statutes, regulations, or both.
2 ICH Q3A defines a new drug substance (also referred to as a new molecular entity or new chemical entity) as a designated
therapeutic moiety that has not been previously registered in a region or member state. The definition also states that a new drug substance
may be a complex, a simple ester, or a salt of a previously approved drug substance.